Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.63 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.63 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.63 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.63 |
| ▸ | CDC7 | O00311 | 4/20 | 0.56 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.56 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.56 |
| ▸ | PIM1 | P11309 | 2/20 | 0.56 |
| ▸ | PRKACA | P17612 | 2/20 | 0.56 |
| ▸ | CDK2 | P24941 | 2/20 | 0.56 |
| ▸ | GSK3B | P49841 | 2/20 | 0.56 |
| ▸ | HIPK2 | Q9H2X6 | 2/20 | 0.56 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.56 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.56 |
| ▸ | BRD4 | O60885 | 1/20 | 0.56 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.55 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.55 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.55 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 0.55 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19832095 | 1.00 | AURKA (0.63) | AURKAAURKBINCENPTPX2CDC7 | |
| SCHEMBL2529049 | 0.82 | CDC7 (0.53) | AURKAAURKBINCENPTPX2CDC7 | |
| SCHEMBL5618155 | 0.80 | TGFBR1 (0.71) | CDC7ROCK2MAP4K4PIM1PRKACA | |
| SCHEMBL29869901 | 0.80 | CDC7 (0.68) | CDC7ROCK2MAP4K4PIM1PRKACA | |
| SCHEMBL856823 | 0.80 | CDC7 (0.68) | CDC7ROCK2MAP4K4PIM1PRKACA | |
| SCHEMBL3740263 | 0.80 | CAMKK2 (0.69) | AURKAAURKBCDC7ROCK2MAP4K4 | |
| SCHEMBL29869781 | 0.79 | TGFBR1 (0.60) | CDC7ROCK2MAP4K4PIM1PRKACA | |
| SCHEMBL857678 | 0.78 | IKBKE (0.64) | CDC7ROCK2MAP4K4PIM1PRKACA | |
| SCHEMBL29869591 | 0.77 | CDC7 (0.60) | CDC7ROCK2MAP4K4PIM1PRKACA | |
| SCHEMBL29870401 | 0.77 | CDC7 (0.60) | CDC7ROCK2MAP4K4PIM1PRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-11447505-B1 | Pyrrolo[2,3-b]pyridine compounds and their use in the treatment of cancer | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2022-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11447505-B1 | Pyrrolo[2,3-b]pyridine compounds and their use in the treatment of cancer | PDXK, CCNK, CDC42BPB | AURKA 316/4885AURKB 81/4885INCENP 2844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.